The Effect of Early Insulin Therapy on Pancreatic β-Cell Function and Long-Term Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients by Chon, Suk et al.
The Effect of Early Insulin Therapy on Pancreatic β-Cell
Function and Long-Term Glycemic Control in Newly
Diagnosed Type 2 Diabetic Patients
Suk Chon
1,2, Seungjoon Oh
1,2, Sung Woon Kim
1,2, Jin-Woo Kim
1,2, Young Seol Kim
1,2, and Jeong-taek Woo
1,2




Background/Aims: Based on the results of well designed clinical studies, intensive insulin therapy has been
established to improve glycemic control in newly diagnosed diabetes. However, discrepancies exist between the
findings of clinical trials and experiences in general practice. Furthermore, the efficacy of an early insulin therapy
(EIT) - commonly used in general practice - on long-term glycemic control has not been established. Therefore,
we evaluated the effects of EIT on pancreatic β-cell function and glycemic control using insulin-based methods
widely employed in general practice.
Methods: We performed a retrospective cohort study that initially involved reviewing patients’ medical records.
Following a thorough review, 61 patients who received either biphasic or prandial EIT at the time of diagnosis were
enrolled. We then evaluated changes in β-cell function and glycemic control during a 48-month follow-up period.  
Results: Mean HbA1c decreased significantly as a result of EIT from 10.7 ± 1.8% to 6.2 ± 1.1% (p < 0.001). On
average, 2.6 months was required to achieve an HbA1c value < 7%. EIT significantly improved the insulinogenic
index. Glycemic control was well maintained for 48 months. More than 70% of patients were able to maintain
glycemic control following lifestyle modifications or treatment with oral antidiabetic drugs. No significant
differences were identified between patients receiving biphasic EIT and prandial EIT in terms of glycemic control
or pancreatic β-cell function. 
Conclusions: Our results suggest that regardless of the method of delivery, EIT significantly improves β-cell
function and facilitates long-term glycemic control in patients with newly diagnosed type 2 diabetes mellitus.
(Korean J Intern Med 2010;25:273-281)
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INTRODUCTION
Despite the development of new drugs and therapeutic
strategies for treating type 2 diabetes mellitus (T2DM),
achieving long-term glycemic control remains a challenge
[1-3]. Results from the United Kingdom Prospective
Diabetes Study (UKPDS) suggest that deterioration of
glycemic control can be largely attributed to progressive β-
cell loss, irrespective of the nature of pharmacological
intervention [1,2]. Therefore, treatments that can preserve
or improve β-cell function are of great interest in the field
of T2DM therapeutics [3-5].
Recent studies have shown that short-term intensive
insulin therapy (IIT) in patients newly diagnosed with
T2DM produces beneficial effects on β-cell function,
glycemic control, and rate of remission (euglycemic
maintenance without antidiabetic therapy) within 1 year
[4,6-8]. However, these studies applied the IIT by meansof continuous subcutaneous insulin infusion (CSII), and
the study patients were hospitalized or required to make
daily clinic visits for strict, frequent monitoring of glucose
levels and for insulin dose titration. Generally, such
treatment protocols can be employed only in well controlled
clinical trials that are funded and supported by numerous
investigators, health care providers, and sponsors. Such
protocols usually cannot be applied to general practice
due to economic and treatment compliance constraints.
To date, no studies have been conducted to examine the
effects of more convenient methods for delivering early
insulin therapy (EIT) on long-term glycemic control and
improvement of β-cell function in patients newly diagnosed
with T2DM. Our study was designed to determine the
generalizability of results that have been reported in previous
clinical trials. Therefore, we retrospectively evaluated the
effect of EIT on pancreatic β-cell function and long-term
glycemic control in newly diagnosed patients who had
T2DM undergoing treatment in a general outpatient
clinic. Insulin was applied in biphasic or prandial fashion
with or without basal insulin, approaches that are commonly
employed in general practice.
METHODS
Subjects
We retrospectively reviewed the medical records of 378
patients newly diagnosed with T2DM who were treated
between January 2003 and December 2006 in the
Department of Endocrinology and Metabolism at Kyung
Hee Medical Center in the Republic of Korea. Of these
patients, 52 were initially treated with diet and exercise
therapy, 260 with oral antidiabetic drugs (OAD), and 66
with insulin (from the time of diagnosis). Of the 66
patients who received insulin therapy, 61 were treated
with insulin to control severe hyperglycemic symptoms.
The remaining five patients were treated with insulin due
to the presence of comorbid disease: systemic tuberculosis
(n = 2), asthma (being treated by steroid therapy) (n = 1),
chronic renal failure (n = 1), and cancer (n = 1). We
conducted statistical analyses of the data gathered from
the medical records of the 61 patients who were treated
with EIT from diagnosis to control hyperglycemia. During
the follow-up period, we measured glycemic levels, tested
insulin secretory function and insulin resistance, and
examined the medication regimens employed.
Method of insulin therapy
The insulin treatment protocols used in this study are
commonly employed in general practice. Specifically, we
performed biphasic and prandial insulin injections with or
without basal insulin. Patients in the biphasic group were
injected twice daily with commercially available premixed
biphasic human insulin or insulin analog (NovoLet®
30/70 or NovoMix® 30, Novo Nordisk A/S, Copenhagen,
Denmark; or Humulin® 70/30 or Humalog® Mix75/25™,
Eli Lilly and Co., Indianapolis, IN, USA). Patients in the
prandial group were injected three times daily with a
rapid-acting insulin analog (Humalog®), with or without a
daily injection of a long-acting insulin (intermediate
insulin neutral protamine hagedorn [NPH]) at bedtime or
long-acting insulin glargine (Lantus®, Aventis
Pharmaceuticals Inc., Tucson, AZ, USA) in the morning or
at bedtime. Patients were given instructions regarding diet
and the self-monitoring of blood glucose, and shown the
proper techniques for injecting insulin and managing
hypoglycemia.
The ultimate goal of glucose control was to achieve a
glycosylated hemoglobin (HbA1c) level of less than 7%.
Physicians adjusted their patients’ insulin doses to achieve
this target. Patients visited the clinic every 1 to 3 months,
and glycemic status was assessed during each visit by
measuring HbA1c levels. Some patients were treated with
relatively intensive insulin therapy (RIIT). In RIIT, the
method of insulin therapy was the same as for biphasic
or prandial insulin, but clinic visits took place every 1 to 2
weeks during the first month of treatment, and self-
monitoring of blood glucose was emphasized to a greater
degree. 
After the target HbA1c level was reached, insulin therapy
was replaced by diet therapy alone or OAD therapy.
Where possible, patients underwent a 75 g standard oral
glucose tolerance test (OGTT) at baseline and after reaching
the target HbA1c level. Insulin treatment was halted
the day before posttreatment OGTT. We retrospectively
reviewed changes in treatment regimens during the
follow-up period and classified treatment modalities into
four groups: lifestyle modification (LSM), OAD only, OAD
in conjunction with basal insulin, and biphasic or prandial
insulin with or without basal insulin. We defined the
absolute insulin retreatment group (AIRT) as patients
who received insulin injections after completing EIT.
Patients who received no insulin after completing EIT were
defined as the non-AIRT group. 
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Clinical and biochemical parameters were tested at the
same time the OGTT was performed. Blood samples were
collected 10 to 12 hours after overnight fasting to determine
baseline levels of total serum cholesterol, triglycerides,
high density lipoprotein-cholesterol (HDL-C), insulin, and
C-peptide. A solution containing 75 g of glucose was then
immediately administered (orally) over a 5-minutes period.
Blood glucose levels were measured at 30, 60, 90, and 120
minutes, and insulin and C-peptide levels at 30 minutes.
Plasma glucose levels were determined by the hexokinase
method using an automatic glucose analyzer (Hitachi,
Tokyo, Japan). Total serum cholesterol and triglyceride
levels were determined by an enzymatic assay and serum
HDL-C levels by a precipitation assay. Low density
lipoprotein-cholesterol (LDL-C) levels were calculated
using the Friedewald equation. Serum insulin and C-
peptide levels were measured using immunoradiometric
assays: insulin - Insulin RIA Bead II; C-peptide - Daiichi
III (both SRL, Tokyo, Japan). HbA1c was measured by
high-performance liquid chromatography using a G7
HPLC analyzer (Tosoh Corporation, Tokyo, Japan). 
Measurement of insulin resistance and β β-cell
function
1) Insulin resistance: the homeostasis model assessment
of insulin resistance (HOMAIR) [9,10] was calculated
as follows:
HOMAIR = (FPG ×FPI) / 405
(FPG: fasting plasma glucose, mg/dL; FPI: fasting
plasma insulin, µU/mL)
2a) β-cell function: the insulinogenic index (IGI), which
is commonly used as an indicator of β-cell function
(10), was calculated from the OGTT data as follows: 
IGI = (Ins30 - Ins0) / (Glc30 - Glc0)
(Glc0: fasting plasma glucose, mg/dL; Glc30: plasma
glucose at 30 minutes during OGTT, mg/dL; Ins0:
fasting plasma insulin, µU/mL; Ins30: plasma
insulin at 30 minutes during OGTT, µU/mL)
2b) β-cell function: the acute C-peptide response (ACR)
was calculated as follows: 
ACR = (C-pep30 - C-pep0) ×1000 / (Glc30 - Glc0)
(Glc0: fasting plasma glucose, mg/dL; Glc30: plasma
glucose at 30 minutes during OGTT, mg/dL; C-pep0:
fasting plasma C-peptide, ng/mL; C-pep30: plasma
C-peptide at 30 minutes during OGTT, ng/mL)
2c) β-cell function: the homeostasis model assessment
of β-cell function (HOMAβ) [9] was calculated as
follows:
HOMAβ= 20 ×FPI / (FPG - 3.5)
(FPG: fasting plasma glucose, mmol/L; FPI: fasting
plasma insulin, mU/L) 
Statistical analysis
Statistical analyses were performed using SPSS version
13.0 (SPSS Inc., Chicago, IL, USA). Normally distributed
data (i.e., relating to continuous variables) are presented as
means ± standard deviations, and non-normally distributed
data (i.e., those relating to triglyceride, IGI, ACR, HOMAβ,
and HOMAIR) as median (interquartile range, IQR).
Student’s t tests and Mann-Whitney U tests were
respectively used to compare normally distributed and
non-normally distributed data from the biphasic and
prandial groups. Chi-square tests were used to analyze
dichotomous variables. Paired Student’s t tests were used
to compare data relating to pre- and post-EIT continuous
variables, and Wilcoxon signed-rank tests data relating to
pre- and post-EIT noncontinuous variables. In cases in
which the treatment method was not changed, missing
HbA1c data were replicated from data collected 1 month
before or after the missing time point, since HbA1c levels
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Table 1. Baseline demographics and clinical
characteristics (across all treatment groups)
Parameters
Age, yr 48.3 ± 11.5
Sex (M/F)a 37/24
Body mass index, kg/m2 25.0 ± 3.5
Abdominal circumference, cm 88.8 ± 10.1
HbA1c, % 10.7 ± 1.8
Fasting plasma glucose, mg/dL 213.0 ± 55.7
Plasma glucose 2 hr post-loading, mg/dL 387.5 ± 74.2
Insulinogenic indexb 0.010 (0.065)
Acute C-peptide responseb 0.000 (7.393)
HOMAβb 15.3 (21.3)
HOMAIRb 2.8 (3.8)
Total cholesterol, mg/dL 205.6 ± 34.0
Triglycerides, mg/dLb 153 (163)
LDL-cholesterol, mg/dL 128.6 ± 30.7
HDL-cholesterol, mg/dL 39.8 ± 11.0
Systolic blood pressure, mmHg 124 ± 17
Diastolic blood pressure, mmHg 81 ± 11
Method of insulin therapy (Biphasic/Prandial)a 26/35
Values are presented as mean ± SD unless otherwise indicated.
HOMA, homeostasis model assessment; IR, insulin resistance;
LDL, low density lipoprotein; HDL, high density lipoprotein.
aValues are presented as sample size.
bValues are presented as median (interquartile range).represent the average glycemic status over a period of 2 to
3 months. Glycemic control during the 48-month follow-
up period was analyzed by two methods: a trend analysis
of glycemic control performed using patients’ HbA1c
values (recorded trimonthly) and a repeated measures
analysis of variance. A pvalue < 0.05 was considered to be
statistically significant.  
RESULTS
Baseline demographics and clinical characteristics of
the 61 patients (biphasic group, n = 26; prandial group, n
= 35) are shown in Table 1. The majority of the patients
were men (n = 37), and the mean patient age was 48.3 ±
11.5 years. Mean patient body mass index (BMI) was 25.9
± 3.5 kg/m2, which falls in the obese range according to
the criteria proposed for the Asia-Pacific region [11]. Mean
abdominal circumference was 88.8 ± 10.1 cm. Despite
being newly diagnosed with T2DM, the patients were
severely hyperglycemic, with a mean FPG of 213 mg/dL,
a mean 2 hours post-load plasma glucose level of 387.7 ±
74.2 mg/dL, and a mean initial HbA1c of 10.7 ± 1.8%. In
addition, the patients’ pancreatic β-cell function was
markedly reduced (IGI 0.010 [0.065]; ACR 0.000 [7.393];
HOMAβ 15.3 [21.3]), and insulin resistance was elevated
(HOMAIR 2.8 [3.8]). Patient blood pressure was normal
and lipid profiles dyslipidemic.  
Effects of early insulin therapy on glycemic
control and pancreatic β β-cell function
Three months following the initiation of EIT, mean
HbA1c had decreased significantly from 10.7 ± 1.8% to 6.2
± 1.1% (p< 0.001). The proportion of patients who achieved
the target HbA1c (< 7%) at 3 months post-EIT was 78.7%,
and the proportion that achieved the target HbA1c within
6 months was 85.2%. The mean duration of EIT necessary
to reach the target HbA1c was 2.6 ± 1.1 months. Mean total
duration of EIT was 4.9 ± 7.1 months. Prior to treatment
with EIT, no significant differences in HbA1c or pancreatic
β-cell function (IGI, ACR) were observed between patients
who achieved the HbA1c target and those who did not.
However, following treatment with EIT, the mean IGI of
the patients who reached the HbA1c target tended to be
higher than that of those who did, although the difference
was not  significant (p= 0.126). 
With the exception of two patients who dropped out
during the 48-month follow-up period and five patients
who persisted with EIT during the follow-up period on the
advice of their physician, the remaining patients (n = 54)
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Table 2. Comparison of biphasic and prandial group characteristics
Characteristics Biphasic (n = 26) Prandial (n = 35)
Age, yra 43.4 ± 12.4 52.1 ± 9.3
Body mass index, kg/m2 24.7 ± 3.5 25.2 ± 3.5
Abdominal circumference, cm 87.2 ± 10.3 90.0 ± 9.9
HbA1c, % 10.5 ± 1.9 10.8 ± 1.7
Duration of early insulin therapy, mon 6.7 ± 7.6 3.7 ± 6.7
Time until HbA1c reduced to < 7%, mon 2.5 ± 1.0 2.7 ± 1.1
Number of patients to achieve HbA1c < 7% at 3 mon, % (n = 25/34) 20 (80) 28 (82.4)
Number of patients to achieve HbA1c < 7% at 6 mon, % (n = 25/34) 21 (84) 31 (91.2)
β-cell function prior to EIT n = 26 n = 33
Insulinogenic indexb 0.009 (0.046) 0.012 (0.092)
Acute C-peptide responseb 0.000 (9.605) 1.134 (6.663)
HOMAβb 13.9 (16.5) 18.3 (21.6)
β-cell function following EIT n = 13 n = 27
Insulinogenic indexb,c 0.269 (0.886) 0.191 (0.178)
Acute C-peptide responsea,b,c 30.055 (65.070) 14.539 (17.690) 
HOMAβb,c 70.3 (108.5) 44.9 (61.8)
Values are presented as mean ± SD unless otherwise indicated.
EIT, early insulin therapy; HOMA, homeostasis model assessment.
aComparison between the biphasic and prandial groups, p < 0.05.
bValues are presented as the median (interquartile range).
cComparison between values pre- and post-EIT treatment, p < 0.001.changed their treatment modality to LSM or OAD. The
mean follow-up duration was 36.6 ± 18.6 months. After
this change in treatment modality, the significant
improvement in glycemic control observed in most
patients was maintained for the duration of the 48-month
follow-up period (Fig. 1). Specifically, a repeated measures
analysis of variance indicated that glycemic control at each
follow-up time point (50 patients at year 1, 38 at year 2, 24
at year 3, and 15 at year 4) was well maintained (p< 0.001).
Plasma glucose concentrations during the OGTT were
significantly improved following EIT (p < 0.001). In
addition, pancreatic β-cell function significantly improved.
Notably, significant improvements in IGI and ACR were
observed (Fig. 2), and the HOMAβ index improved from
15.3% (21.3) to 47.2% (68.54) (p < 0.001). Finally, the
HOMAIR index improved from 2.9 (IQR 3.8) to 2.2 (2.5)
(p< 0.001). 
Comparison of glycemic control and pancreatic β β-
cell function between patients in the biphasic and
prandial groups
Table 2 shows the demographics and clinical characteristics
of the patients in the biphasic and prandial groups. With
the exception of mean age and duration of EIT, no
significant differences were observed in the baseline
characteristics between the two groups. While the mean
patient age was significantly higher in the prandial group
than in the biphasic group (p = 0.003), overall duration of
EIT for patients in the biphasic group tended to be longer
than that for patients in the prandial group, although the
difference was not significant (p = 0.111). No significant
differences were observed in the duration of EIT required
to achieve the target HbA1c. In both the biphasic and prandial
groups, pancreatic β-cell function improved significantly
following EIT. No significant differences in pancreatic β-
cell function (baseline or post-EIT) were detected between
the biphasic and prandial groups. However, significant
differences were seen between the two groups with respect
to ACR, which was significantly higher in the biphasic
group than the prandial group (p = 0.029). Percentages of
patients reaching the target HbA1c were comparable. No
significant differences were detected between the two
groups with respect to glycemic control during the follow-
up period (data was not shown).
Changes in treatment modality during the 48-
month follow-up period
After attaining the target HbA1c, 54 patients (88.5%)
were treated with LSM or OAD only. The remaining five
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Figure 2. Changes in β-cell function following early insulin therapy (EIT). Insulinogenic index (A) and acute C-peptide response (B)
increased significantly following EIT (p < 0.001). Solid lines indicate median values, and dashed lines denote mean values. Data are
presented as the median (interquartile range).
A B
Figure 1. Changes in HbA1c following early insulin therapy
(EIT). Immediately following EIT, glycemic control improved
significantly (p < 0.001); the improvement was maintained
during the follow-up period. patients did not undergo changes in their treatment
regimen but instead continued with insulin therapy. More
than 70% of patients continued with their LSM or OAD
treatment for the entire 4-year follow-up period (Fig. 3).
No significant differences in treatment method (LSM/
OAD) existed between the biphasic and prandial groups.
Of the 43 patients who completed the entire follow-
up period, those receiving AIRT (n = 20) displayed no
differences in HbA1c at the 3- and 6-month follow-up
time points from non-AIRT patients. However, HbA1c
was significantly higher in the AIRT group than in the
non-AIRT group at the 9-, 12-, 15-, 21-, 24-, and 30-month
follow-up time points (p< 0.05). No significant differences
were observed in baseline pancreatic β-cell function
between AIRT and non-AIRT patients. However, following
treatment with EIT, the non-AIRT group patients displayed
significantly better β-cell function than AIRT patients
(IGI: AIRT 0.144 [0.201], non-AIRT 0.226 [0.341],  p= 0.098;
ACR: AIRT 11.904 [21.210], non-AIRT 24.077 [55.109],
p= 0.040).
Comparisons between the RIIT and non-RIIT groups
No significant differences were noted in the proportion
of biphasic or prandial insulin-treated patients or baseline
HbA1c levels between the RIIT (n = 30) and non-RIIT
(n = 23) groups. Moreover, no significant differences
were observed in the length of time taken by the RIIT and
non-RIIT patients to reach the target HbA1c (2.4 ± 0.8
months and 2.9 ± 1.4 months, respectively). However, the
overall duration of EIT was significantly shorter in the
RIIT group than in the non-RIIT group (2.8 ± 2.5 months
vs. 8.5 ± 10.4 months, p= 0.017). Furthermore, a significantly
higher proportion of patients in the RIIT group had reached
the target HbA1c by the third month of follow-up than
patients in the non-RIIT group (89.5% vs. 66.7%, p =
0.042). Also, significantly fewer RIIT patients fell into
the AIRT group than non-RIIT patients (35.7% vs. 64.3%,
p< 0.001). During the 4-year follow-up period, more than
80% of the patients in the RIIT group were able to
maintain glucose control with LSM or OAD only,
compared to fewer than 40% of the non-RIIT patients (p
< 0.001). However, no significant differences existed
between the RIIT and non-RIIT groups with respect to
pre- and post-EIT pancreatic β-cell function.
DISCUSSION
The primary objective when treating T2DM is the
prevention or delay of diabetic complications through
optimal glycemic control, which ultimately improves
patients’ quality of life. Despite such clear objectives, T2DM
is a progressive, complicated disease, and maintaining
long-term glycemic control and preventing complications
are very difficult.
Many institutions have developed treatment guidelines
for T2DM. A consensus meeting of the American Diabetes
Association and European Association for the Study of
Diabetes suggested lifestyle intervention and metformin
therapy at diagnosis and the early application of insulin
therapy if a patient does not meet the primary target
(HbA1c < 7%) [12]. According to these guidelines, early
intervention with insulin therapy and lifestyle modification
is recommended in cases of severe, uncontrolled hyper-
glycemia. Although many clinical studies [1,3,4] have
reported the short- and long-term effects of various drugs
on glycemic levels in newly diagnosed patients with
T2DM, studies performed in general practice have been
limited. 
In 2003, we began using EIT for the treatment of
T2DM in our outpatient practice. It was our belief that
rapid amelioration of glucotoxicity would improve β-cell
function and thus facilitate long-term glycemic control. In
this study, we retrospectively analyzed the results we
obtained during the 4-year period. 
We found that an average of 3 months of EIT was needed
to decrease HbA1c to the near-normal level of 6.2 ± 1.1%.
Patients were treated according to our usual clinical care
schedules. Although we titrated the insulin dosage every 2
to 4 weeks during the initial treatment period, which
represents a relatively low frequency compared to the
treatment intervals reported in previous clinical trials
[4,6-8], glycemic control rapidly improved, with an
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Figure 3. Changes in treatment modality during the 4-year
follow-up period. OAD, oral antidiabetic drugs.average HbA1c decrease of 4 percentage points within 3
months. The proportion of patients who achieved the
target HbA1c of < 7% within 6 months of EIT (85.2%) was
higher than that reported in a previous study by Hirao et
al. (32.1%) [13]. The two studies were different in terms of
previous duration of diabetes. In the study by Hirao et al.
[13], drug-naïve patients in the biphasic group had
suffered from diabetes for an average of 6.58 ± 8.17 years
and those in the multiple daily injection (MDI) group an
average of 10.05 ± 13.59 years. In contrast, our patients
had all been diagnosed within the past year. This suggests
that the shorter time since diagnosis may have contributed
to the recovery of β-cell function and amelioration of
hyperglycemia in our study patients. 
Following the discontinuation of EIT, most patients
were able to maintain long-term glycemic control during
the 4-year follow-up period. No significant differences
were observed in short-term glycemic control between the
biphasic and prandial groups, consistent with the results
reported by Hirao et al. [13]. Similarly, no significant
differences in long-term glycemic control were detected
between the two treatment groups.
Recently, Weng et al. [4] reported a 40 to 50% remission
rate at 1-year follow-up in patients given transient IIT (2
to 5 weeks). We ourselves found that improvements in
glycemic control were well maintained after the withdrawal
of EIT for the remainder of the 4-year follow-up period,
despite the variety of treatment modalities employed
following the cessation of EIT. Specifically, 70 to 80% of
patients treated with LSM or OAD alone maintained a
reasonable glycemic status. We presume that rapid
improvement of glucotoxicity results in early restoration
of pancreatic β-cell function, which in turn facilitates long-
term glycemic control. Pancreatic β-cell function following
the discon-tinuation of EIT was better in the non-AIRT
group than in the AIRT group. This suggests that the
degree of improvement in pancreatic β-cell function
impacts upon the degree to which glycemic control is
maintained.
Data from several studies indicate that EIT prolongs
endogenous insulin secretion and promotes metabolic
control in both type 1 and type 2 diabetes [4,14,15]. The
shorter the period of prior glucotoxicity is, the more likely
the restoration of β-cell function will be [16]. Many studies
have reported that the rapid correction of hyperglycemia
improves β-cell function and insulin resistance [17-19]. In
previous studies [3,4], the elimination of glucotoxicity and
improved insulin secretion were achieved not only through
intensive insulin therapy, but also with oral antidiabetic
therapy. However, the effect of the latter was highly transient
and no oral antidiabetic agent has yet been shown to
profoundly reverse the inexorable β-cell deterioration and
worsened glycemia in type 2 diabetes [20]. Although few
comparative studies have investigated the ability of oral
antidiabetic agents and early insulin therapy to control
glycemia, a study performed in a Chinese population [4]
showed higher insulin-secreting capacity in subjects
treated with insulin than in those who received oral antidi-
abetics. Therefore, as well as eliminating glucotoxicity,
early insulin treatment may also help to restore pancreatic
β-cell function. Insulin therapy itself would be expected to
decrease the demand placed on pancreatic β-cells to
secrete insulin. This is referred to as the “β-cell rest” effect
and the results of previous studies seem to support this
hypothesis. Insulin has been reported to possess anti-
inflammatory properties and to directly influence β-cell
growth and survival [21]. The mechanisms by which it
improves β-cell function remain unclear. However, a
prospective study involving eight university medical
centers is being conducted at our institute to determine
the effects of intensive glycemic control, achieved through
early IIT or early combined oral antidiabetic therapy, on
the restoration of β-cell function and on long-term glycemic
control (www.clinicaltrial.gov, NCT00474838). We
believe that the results of this study will provide invaluable
insights.
Unfortunately, the optimal period of euglycemia for the
full amelioration of glucotoxicity and restoration of β-cell
function remains unknown. In a study performed on rats
suffering from streptozotocin-induced diabetes, 4 weeks
of insulin intervention resulted in improved glycemic
control and increased β-cell mass, islet insulin content,
and proinsulin production [22]. Garvey et al. [23] showed
that 24-hour integrated insulin secretion and second-
phase insulin secretion, but not first-phase insulin secretion,
improved in patients with T2DM following treatment with
CSII. In clinical studies on IIT [4,6-8], the duration of IIT
has typically been 2 to 3 weeks. The rationale behind the
choice of treatment period has not been properly detailed
in these studies. McFarlane et al. [14] reported that
pancreatic β-cell function stably improved during 8 to 12
weeks of euglycemia following the initial restoration of
euglycemia. It was not clear, however, that β-cell function
would be sufficiently improved during the initial period of
euglycemia to sustain the long-term maintenance of
normal fasting and postprandial glucose levels. We also
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paralleled the improvement in glycemic status over the
course of 2 to 3 months, reflected the amelioration of
glucotoxicity during the same time period. 
The present study involved retrospective observational
analyses. We took the decision to continue EIT until the
target HbA1c of < 7.0% was reached. This took an average
of 2.6 ± 1.1 months, similar to the findings of McFarlane et
al. [14]. We cannot directly compare our findings with
those of other studies because of differences in baseline
characteristics and treatment protocols. Nevertheless, we
tentatively propose that the optimal duration of EIT for
long-term glycemic control is either 3 months or however
long is required to achieve a normal HbA1c level.
In this study, RIIT patients had a significantly shorter
duration of EIT than non-RIIT patients and more of them
achieved the target HbA1c by the 3-month time point.
Following EIT, a larger proportion of patients in the RIIT
group were treated with LSM or OAD alone than in the
non-RIIT group. Some investigators have suggested that
active titration of insulin, which requires frequent contact
with health care providers, facilitates the achievement of
effective glycemic control [24,25]. In our study, care patterns
in the RIIT group may have influenced patient compliance
and induced other behavioral changes.
Research into the effects of biphasic insulin treatment
on pancreatic β-cell function has been limited [26,27].
Moreover, a literature search revealed few studies that
have compared the effects of biphasic and prandial EIT on
pancreatic β-cell function. In the present study, biphasic
and prandial EIT were equally effective for achieving
glycemic control and restoration of pancreatic β-cell
function in patients newly diagnosed with T2DM. Based
upon the results of our study, we suggest that biphasic EIT
is as effective as prandial EIT with or without basal
insulin. We further found that insulin treatment protocols
commonly employed in outpatient clinics, both biphasic
or prandial, were as effective at achieving short- and long-
term glycemic control and restoration of pancreatic β-cell
function as intensive insulin therapy in well designed and
well funded clinical studies requiring patient admission,
frequent visits, and use of CSII or MDI. 
Our study has some limitations. First, it was a retro-
spective, non-randomized, and uncontrolled study. In
addition, some data were missing and losses occurred
during follow-up. Despite these limitations, our findings
may be more clinically useful than those of controlled
clinical trials. The suggestion was made that the goals of
clinical research trials are not always in line with clinical
medicine’s goal of optimal patient care [28]. The failure of
physicians and patients to understand the difference
between scientific research and personalized medical
treatment has been termed “therapeutic misconception”
[29]. Several reports have identified contributing factors
and potential solutions [30-32]. We were able to avoid
the problem of therapeutic misconception because our study
employed a retrospective design and drew patients from
general practice. Moreover, our patients were offered
personalized insulin treatment. Our study therefore allowed
us to assess the effects of early insulin therapy in a genuine
clinical context.
In conclusion, our results suggest that EIT based on
insulin treatment protocols that are commonly employed
significantly improves β-cell function and facilitates long-
term glycemic control in patients newly diagnosed with
T2DM. 
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